| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1998;98:2108-2116.)
© 1998 American Heart Association, Inc.
Clinical Investigation and Reports |
Vascular Endothelial Growth Factor (VEGF) Expression in Human Coronary Atherosclerotic Lesions
Possible Pathophysiological Significance of VEGF in Progression of Atherosclerosis
From the Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine (M.I., H.I., K.D., Y.O., N.T., K.T., T.I., J.Y., T.-H.C., K.M., K.N.); Department of Pathology, Osaka City University Medical School (M.U., R.K.); Department of Cardiology, Osaka City General Hospital (T.N.); and Department of Anatomy, Osaka City University Medical School (A.K.), Japan; and the Department of Cardiovascular Pathology, Academic Medical Center, University of Amsterdam, The Netherlands (A.E.B.)
Correspondence to Hiroshi Itoh, MD, PhD, Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan. E-mail hiito{at}kuhp.kyoto-u.ac.jp
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background—Vascular endothelial growth factor (VEGF) is an important angiogenic factor reported to induce migration and proliferation of endothelial cells, enhance vascular permeability, and modulate thrombogenicity. VEGF expression in cultured cells (smooth muscle cells, macrophages, endothelial cells) is controlled by growth factors and cytokines. Hence, the question arises of whether VEGF could play a role in atherogenesis.
Methods and Results—Frozen sections from 38 coronary artery segments were studied. The specimens were characterized as normal with diffuse intimal thickening, early atherosclerosis with hypercellularity, and advanced atherosclerosis (atheromatous plaques, fibrous plaques, and totally occlusive lesions). VEGF expression as well as the expression of 2 VEGF receptors, flt-1 and Flk-1, were studied with immunohistochemical techniques in these samples at the different stages of human coronary atherosclerosis progression. The expression of VEGF mRNA was also studied with reverse transcription–polymerase chain reaction. Normal arterial segments showed no substantial VEGF expression. Hypercellular and atheromatous lesions showed distinct VEGF positivity of activated endothelial cells, macrophages, and partially differentiated smooth muscle cells. VEGF positivity was also detected in endothelial cells of intraplaque microvessels within advanced lesions. In totally occlusive lesions with extensive neovascularization, intense immunostaining for VEGF was observed in accumulated macrophages and endothelial cells of the microvessels. Furthermore, VEGF mRNA expression was detected in atherosclerotic coronary segments but not in normal coronary segments. The immunostainings for flt-1 and Flk-1 were detected in aggregating macrophages in atherosclerotic lesions and also in endothelial cells of the microvessels in totally occlusive lesions.
Conclusions—These results demonstrate distinct expression of VEGF and its receptors (flt-1 and Flk-1) in atherosclerotic lesions in human coronary arteries. Considering the multipotent actions of VEGF documented experimentally in vivo and in vitro, our findings suggest that VEGF may have some role in the progression of human coronary atherosclerosis, as well as in recanalization processes in obstructive coronary diseases.
Key Words: angiogenesis • atherosclerosis • coronary disease • immunohistochemistry • pathology
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In 1989, a new factor involved in angiogenesis was isolated, known as vascular endothelial growth factor (VEGF) or vascular permeability factor.1 It may play a role in tumor growth, wound healing, age-related macular degeneration, rheumatoid arthritis, diabetic retinopathy, and collateral formation in ischemic tissue.2
VEGF is reported to potently induce migration and proliferation of endothelial cells (ECs), enhance vascular permeability, and modulate thrombogenicity. VEGF was considered unique among angiogenic growth factors, because its 2 high-affinity receptors with tyrosine kinase domains (flt-1 and Flk-1/kinase insert domain receptor) were thought to be confined to ECs3 ; consequently, VEGF could act as an EC-specific mitogen.4 Studies on knockout mice of VEGF or its receptors have revealed that VEGF plays a critical role in the development and formation of blood vessel networks.5 6 However, recent studies have demonstrated that the gene for the VEGF receptor flt-1 is expressed in human monocytes as well, and the VEGF-induced chemotactic response of human monocytes is mediated via this receptor.7 8 Clauss et al9 also documented that VEGF induces monocyte activation and migration. These data strongly suggest that VEGF plays a role in the chemotaxis of monocytes/macrophages, which is crucial in inflammatory reactions and in wound-repair processes. Recently, we demonstrated that VEGF strongly suppresses the secretion of C-type natriuretic peptide,10 a member of the natriuretic peptide family that acts as a vasoactive peptide secreted by vascular ECs. This, then, raised the possibility that VEGF could indirectly modulate the contraction and growth of smooth muscle cells (SMCs).
It has been shown that VEGF is produced not only by malignant tumor cells of several types but also by cultured SMCs,11 macrophages,12 and ECs.13 The expression of VEGF in these cultured cells appears to be controlled by a variety of growth factors and cytokines. VEGF gene expression is upregulated not only by hypoxia but also by transforming growth factor-ß, angiotensin II, basic fibroblast growth factor, and interleukin-1.2 11 All these factors are known to be expressed in atherosclerotic lesions. Because progression of atherosclerosis relates to alteration of EC function, accumulation of macrophages, phenotypic modulation of SMCs, and neovascularization of the plaque tissue,14 15 one may speculate that VEGF could play a role in atherogenesis.
Thus far, however, we are unaware of any studies that have looked into the potential significance of VEGF in human atherosclerosis. For this reason, we have studied the expression of VEGF as well as its 2 receptors, flt-1 and Flk-1, in human coronary arteries using immunohistochemical analysis and the occurrence of VEGF mRNA using the reverse transcription–polymerase chain reaction (RT-PCR) method.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Materials
Thirty-eight coronary artery segments were harvested at autopsy within 3 hours after death (15 patients; age range, 21 to 72 years). Twelve segments contained diffuse intimal thickening (DIT) but were otherwise normal. Twenty-six contained atherosclerotic lesions characterized histologically either as early atherosclerotic lesions with hypercellularity (n=7) or as advanced atherosclerotic lesions (n=19).16 17 The hypercellular atherosclerotic lesion was defined as a cell-rich intimal lesion composed predominantly of SMCs and macrophages but without an appreciable extracellular lipid core. The advanced atherosclerotic lesions were divided into atheromatous (n=8), fibrous (n=7), and totally occluded lesions (n=4).
The coronary arteries were dissected from the epicardial surface, and a 2-mm slice from each segment was snap-frozen and stored at -80°C. The snap-frozen samples were sectioned serially at 6-µm thickness and fixed in acetone. Every first section was stained with hematoxylin and eosin; the other sections were used for immunohistochemical staining.
Immunohistochemical Staining
The source and specificity of all antibodies used in this study
are summarized in the Table
. For the
identification of VEGF, a rabbit polyclonal antibody was used that was
directed against the 20 amino-terminal residues of human VEGF (Santa
Cruz Biotechnology). The antibody was demonstrated to neutralize VEGF
activity and specifically react with native and denatured (reduced)
VEGF by Western blot.18 For the identification of
flt-1 and Flk-1, rabbit polyclonal antibodies were used (Santa Cruz
Biotechnology). Both antibodies react with flt-1 or Flk-1 of mouse,
rat, and human cell origin but do not cross-react with other tyrosine
kinase membrane receptors.
|
HLA-DR antibody was used to examine the activation state of cells.19 To identify SMCs and to evaluate differences in the state of differentiation, 2 anti-actin markers, 1A4 and CGA7, were used.20 21 22 23
Single Staining
Sections were incubated with the primary antibodies, either
overnight at 4°C or for 1 hour at room temperature. The sections were
then subjected to a 3-step staining procedure, with the use of
streptavidin-biotin complex with horseradish peroxidase for color
detection. Tris-buffered saline was used for washing between the
subsequent incubation steps. Horseradish peroxidase activity was
visualized with 3-amino-9-ethylcarbazole, and the sections were faintly
counterstained with hematoxylin.
The specificity and results obtained with anti-VEGF, flt-1, and Flk-1 antibodies were checked by omitting the primary antibodies and using nonimmune rabbit serum (Dako) as negative control. Human renal tissues served as a positive control.
Immunodouble Staining
For the simultaneous identification of SMCs and
macrophages, sections were double-stained with 1A4 and EBM11,
according to procedures previously reported.24 In
this immunodouble staining, we visualized the enzymatic activity of
ß-galactosidase for 1A4 in turquoise (BioGenex Kit) and the activity
of alkaline phosphatase for EBM11 in red (New Fuchsin Kit, Dako).
To identify cell types that express VEGF, we also performed immunodouble staining for 1A4/VEGF, EBM11/VEGF, and EN-4/VEGF in some sections. In this staining, alkaline phosphatase was visualized with fast blue BB (blue, 1A4, EBM11, and EN-4) and peroxidase with 3-amino-9-ethylcarbazole development (red, VEGF).
Area Quantification of VEGF-Positive Cells and Statistical
Analysis
The total surface area containing VEGF-positive cells was
quantified by use of computer-aided planimetry and expressed as a
percentage of the total surface area of the intima, the so-called
VEGF+ cell area. In addition, the surface area
occupied by VEGF-positive ECs—the so-called
VEGF+ EC area—was quantified similarly and
expressed as a percentage of the total surface area occupied by ECs as
shown by von Willebrand factor (vWF) staining. The luminal
surface area occupied by vWF-positive ECs was also estimated as a
percentage of the whole luminal surface area. Results are expressed as
mean±SD. Statistical comparisons between groups were performed by the
Kruskal-Wallis test followed by multiple comparison with
Scheffé's test. Values of P<0.05 were considered
significant.
RT-PCR Southern Blot Analysis
Normal coronary artery segments with DIT (n=3) and
segments with atherosclerosis containing
atheromatous plaques (n=3) were used. The segments were
selected to be directly adjacent to the ones used for
immunohistochemical investigations. RNAs were isolated from these
coronary segments by the guanidine thiocyanate/CsCl
method. cDNA was synthesized from 5 µg of total RNA primed
with oligo-dT by use of reverse transcriptase (Super Script
II) at 42°C for 1 hour. cDNA (0.5 µg) was subjected to VEGF
PCR with 50 fmol of primers. Primer sequences were
5'-GGACATCTTCCAGGAGTA-3' (human VEGF165 cDNA
nucleotides 232 to 250) and 5'-TGCAACGCGAGTCTGTGT-3'
(nucleotides 555 to 573) for detecting human VEGF mRNA.
Amplification was carried out for 40 cycles with 30 seconds of
incubation at 94°C, 30 seconds at 55°C, and 1 minute at 72°C. A
10-µL aliquot of each RT-PCR reaction mixture was electrophoresed on
a 1.5% agarose gel and hybridized with a specific
oligodeoxyribonucleotide probe for VEGF mRNA
(5'-ATGTGAATGCAGACCAAAGA-3'). After hybridization, the filters were
washed in 3xSSC (1xSSC was 0.15 mol/L NaCl and 0.015 mol/L Na
citrate)/1% SDS for 1 minute at room temperature and for 3 minutes at
4°C.10
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Normal Coronary Arteries (n=12; 5 Patients)
Normal coronary arteries contained various degrees of DIT with 1A4- and CGA7-positive SMCs in the media and in the intima. ECs and SMCs were virtually negative for VEGF (Figure 1
). VEGF staining was found occasionally
in macrophages and occasionally also in some HLA-DR–positive
ECs.
|
The VEGF+ cell area was 0.8±1.1%; the VEGF+ EC area was 0.4±1.1%. In normal coronary arteries with DIT, flt-1 or Flk-1 staining was not detected.
Atherosclerotic Plaques (n=26; 10 Patients)
Hypercellular Atherosclerotic Lesions (n=7; 4 Patients)
Three of the 7 lesions were composed almost solely of SMCs, with
only occasional macrophages scattered throughout the intima.
The vast majority of the SMCs stained positive with both 1A4 and CGA7.
HLA-DR was expressed by macrophages, but only few SMCs and ECs
showed HLA-DR positivity. VEGF-positive staining was seen in some of
the ECs and in some macrophages, particularly those in the
superficial layers of the intima. SMCs showed no VEGF positivity (data
not shown).
The 4 other hypercellular lesions were characterized by numerous
foci of clustered macrophages (Figure 2). Of the SMC markers, only 1A4 was
positive; CGA7 was negative. HLA-DR positivity was found in
macrophages and SMCs associated with the inflammatory cells.
VEGF was distinctly expressed at sites that contained clustered
macrophages (Figure 2). The immunodouble staining for
macrophages (or SMCs) and VEGF-positive cells showed that VEGF
positivity was detected in macrophages and some SMCs as well as
ECs. Vasa vasorum were not observed in the media and atherosclerotic
intima of either one of these hypercellular lesions.
|
The VEGF+ cell area was 29.4±18.3%; the
VEGF+ EC area was 26.4±26.6%. Occasional
aggregating macrophages showed positivity for flt-1 and Flk-1
(Figure 2
).
Advanced Atherosclerotic Plaques
Atheromatous (n=8; 5 Patients)
Advanced atheromatous plaques, characterized
by a distinct lipid core and fibrous cap, contained abundant
macrophages and SMCs (Figure 3).
The vast majority of these cells expressed HLA-DR. The SMCs within the
fibrous cap stained positive with 1A4 but did not stain with CGA7. The
immunodouble staining revealed that in the fibrous cap, VEGF positivity
was seen in macrophages and SMCs adjacent to inflammatory cells
as well as a good number of ECs (Figure 3), most of which appeared to
colocalize with HLA-DR positivity. In the plaque-free wall of eccentric
atheromatous lesions, ECs were frequently positive for
VEGF, whereas the underlying SMCs stained negative for VEGF (Figure 3).
Although there were some EC-denuded areas, the immunodouble staining
for ECs and VEGF-positive cells revealed that almost all ECs were
uniformly positive for VEGF, and there were no VEGF-positive SMCs or
macrophages underlying these EC-denuded areas (Figure 4). Five of the 8
atheromatous lesions contained microvessels within the
plaque, 4 of which showed VEGF positivity of the ECs of the vessels
(Figure 5).
|
|
|
The VEGF+ cell area was 24.4±8.0%; the
VEGF+ EC area was 18.8±21.3%. In these plaques,
clustered macrophages were positive for flt-1 and Flk-1 (Figure 3).
Fibrous (n=7; 6 Patients)
In fibrous plaques, characterized by dense collagen without an
appreciable lipid core and with only sparse and scattered inflammatory
infiltrates, only a few cells were VEGF-positive (data not shown).
Microvessels were found in 6 of the 7 fibrous plaques; only 2 plaques
showed VEGF staining in ECs of the microvessels.
The VEGF+ cell area was 2.6±5.2%; the VEGF+ EC area was 0.8±1.8%.
Total Occlusion (n=4; 2 Patients)
Under this subheading, we have also included cases with subtotal
occlusion (luminal stenosis of >90%).
Two sites from 1 patient both showed an advanced fibrous plaque
with extensive proliferation of microvessels extending from the
adventitia through the media and the plaque into the occluded luminal
area. The central preexistent luminal remnant was lined by
macrophages (Figure 6). Areas
within the plaque that contained conspicuous microvessels also showed
accumulation of macrophages (Figure 6). There were only a few
1A4-positive SMCs within the plaque. VEGF staining revealed strong
positivity in macrophages and in the ECs of the microvessels
(Figure 6); these positive sites appeared to colocalize with those of
HLA-DR–positive ECs and macrophages. The immunodouble staining
for ECs and VEGF-positive cells demonstrated that most of the ECs of
the microvessels within the plaque showed VEGF positivity (Figure 6).
The HLA-DR–positive ECs and macrophages were also positive for
both flt-1 and Flk-1 immunostainings (Figure 6).
|
The 2 remaining occluded lesions (from another patient) were also basically fibrous in nature, although with fewer macrophages and with fewer and smaller microvessels with narrowed lumen. In these instances, staining for VEGF provided only few positive macrophages and only occasionally some positivity of ECs of the microvessels.
Area Quantification and Statistical Analysis
The VEGF+ cell area was significantly higher
(P<0.05) in hypercellular atherosclerotic lesions and in
advanced atheromatous plaques than in DIT (Figure 7A). The VEGF+ EC
area in hypercellular atherosclerotic lesions was significantly higher
than in DIT (P<0.05) (Figure 7B).
|
The luminal surface area occupied by vWF-positive ECs did not differ among 4 groups with 92.5±4.7% (93.9±4.3% in DIT, 93.1±5.8% in hypercellular atherosclerotic lesions, 90.6±4.0% in advanced atheromatous plaques, 91.8±4.9% in advanced fibrous plaques).
RT-PCR Southern Blot Analysis of VEGF mRNA
Expression
As shown in Figure 8, human renal
tissue, used as positive control, gave 2 distinct signals with 428 and
356 bp, which corresponded to mRNA for VEGF189
and VEGF165, respectively. Advanced
atheromatous plaques gave 1 distinct band with 356 bp.
In contrast, normal coronary arteries gave substantially no
signals in RT-PCR Southern blot analysis.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In humans, in vivo studies have demonstrated the expression of VEGF mRNA or VEGF protein in the normal kidney, in a variety of tumors, in heart transplants, and in rheumatoid synovial tissue. However, to the best of our knowledge, this is the first study to demonstrate the expression of VEGF protein and VEGF mRNA in the progression of human coronary atherosclerosis.
The present study clearly showed that positive immunostaining for VEGF in human coronary atherosclerotic plaques was always related to the occurrence of abundant HLA-DR–positive cells. Our quantitative analysis unequivocally demonstrated a significantly higher VEGF+ cell area in hypercellular atherosclerotic lesions and in atheromatous plaques than in normal coronary arteries with DIT. Moreover, the present study also showed distinct expression of VEGF mRNA in human coronary atherosclerotic plaques but not in normal coronary arteries. Previous studies have revealed that a marked increase in the number of HLA-DR–positive cells in human atherosclerotic lesions is linked closely to inflammatory processes within the atherosclerotic plaques and clinically to progressive disease.16 19 Hence, our findings strongly suggest that VEGF is closely related to the progression of coronary atherosclerosis in humans.
Ross et al14 promoted the concept that dysfunction of ECs, with subsequent infiltration of circulating monocytes/lymphocytes, is the primary event for atherogenesis. It is of interest, therefore, that ECs of normal coronary arteries, albeit with DIT, in our study did not show immunostaining for VEGF. Conversely, once activated (HLA-DR+) ECs were identified in atherosclerotic lesions, positive immunostaining of ECs was also found. Indeed, the VEGF+ EC area in atherosclerotic lesions was significantly higher than that of normal coronary arteries. It is tempting to consider these differences as an integral part of the change in EC function in relation to atherogenesis. This is more likely because VEGF has been recognized not only to stimulate EC proliferation, increase vascular permeability, and alter thrombogenicity25 but also to induce migration of human mononuclear phagocytes/monocytes and stimulate their expression of tissue factor.7 8 9
In our samples, there were some EC-denuded areas. The luminal
surface area occupied by ECs, however, did not differ among 4 groups in
different stages of atherosclerosis (91% to 94%).
Because we did not detect any thrombus formation in these denuded
areas, we consider that the observed endothelial
denudation possibly occurred during our sampling, sectioning, and
immunohistochemical staining procedure. Although the extent of
endothelial denudation was almost the same in each
stage of atherosclerosis, endothelial
expression of VEGF differed significantly, as shown in Figure 7. In
addition, the immunodouble staining for ECs and VEGF-positive cells
revealed that there seemed to be no apparent effect of
endothelial denudation on VEGF positivity for the
bordering ECs and the underlying SMCs or macrophages (Figures 3B and 4).
The present study of immunodouble staining demonstrated that macrophages that accumulated in atherosclerotic lesions showed positive immunostaining for VEGF. This finding is in keeping with previous reports, which have shown that activated macrophages in culture12 and macrophages involved in rat and guinea pig wound healing26 produce VEGF. Clauss et al9 recently demonstrated that VEGF promotes monocyte migration in vitro. Moreover, Shen et al7 and Barleon et al8 showed that migration of human monocytes in response to VEGF is mediated via flt-1. We also confirmed that macrophages that accumulated in atherosclerotic lesions expressed flt-1 and Flk-1. The observations in experimental work and our present findings support the hypothesis that VEGF, which originated from activated macrophages, could recruit further macrophages into the lesions through the VEGF receptors.
The present study, using 2 actin markers, 1A4 and CGA7,
revealed that SMCs in human coronary arteries showed
differences in VEGF staining positivity, which related to their
phenotypic differentiation as judged by the characters of these 2
different actin markers (see the Table). CGA7-positive (fully
differentiated20 21 ) SMCs in the media did not
show VEGF immunoreactivity. Within atherosclerotic lesions, conversely,
our immunodouble staining analysis revealed that although
CGA7-positive SMCs did not stain for VEGF, less differentiated SMCs
(CGA7-/1A4+)21 22 23
showed distinct positivity for VEGF. The results indicate that SMCs
with a phenotypic shift toward a less differentiated state are capable
of expressing VEGF.
The presence of microvessels within human coronary atherosclerotic lesions has been recognized for some time, but their potential role in promoting the progression of the disease has been revealed only recently.15 27 In the present study, we detected intraplaque microvessels in advanced atherosclerotic plaques. We also demonstrated distinct VEGF expression in early atherosclerotic lesions that contained abundant clustered macrophages. This is of considerable interest, because one could argue that VEGF expression within the plaque may be an important phenomenon preceding the formation of the intraplaque microvessels. Recent animal studies have pointed out that VEGF is a key mediator of neovascularization associated with a variety of disorders.28 These experimental data and our present findings suggest that VEGF could be one of the growth factors involved in the development of intraplaque microvessels in human coronary arteries.
In totally occlusive lesions, new vessels are formed as part of the organization and recanalization response. In the present study, 2 different types of the totally occlusive lesions were observed. Obstructive lesions with numerous macrophages and extensive neovascularization throughout the arterial wall, considered to be part of an ongoing process of organization and recanalization, showed intense immunostaining for VEGF of the ECs of the microvessels as well as of the accompanying macrophages. In contrast, in the lesions in which the occluded lumen was replaced by connective tissues with less macrophage infiltration and atrophic microvessels, considered to be at a stage of regression, there was only weak or no immunostaining for VEGF. Hence, these observations support the hypothesis that VEGF expression may be upregulated during the development of organization and recanalization and downregulated at the end stage of recanalization or at the subsequent regression stages of the recanalized tissues in humans. Furthermore, flt-1 and Flk-1 expressions were detected in the ECs of the microvessels and macrophages in the stage of organization and recanalization. Taken together, our results could provide evidence that in human coronary arteries, angiogenesis for recanalization could be induced by VEGF derived from macrophages and ECs and be instrumental in autocrine and paracrine fashion.13
Recently, VEGF has been promoted as a potential new therapeutic agent for occlusive vascular diseases. Intra-arterial administration of recombinant human VEGF165 markedly increased the development of collateral vessels and associated perfusion in a rabbit model with chronic hindlimb ischemia.28 Gene therapy with VEGF for human vascular diseases has recently started.29 Our observations of totally occluded coronary arteries may provide further rationale for such clinical trials. At the same time, however, a word of caution should be heard, because our observations also suggest that VEGF itself may promote the process of atherogenesis. In fact, it has already been reported that the in vivo introduction of human VEGF165 cDNA into rabbit carotid arteries by the hemagglutinating virus of Japan/liposome method induced prominent angiomatoid proliferation of ECs and thickening of the intima due to fibromuscular hyperplasia.30 Lazarous et al31 also reported that VEGF administration exacerbated neointimal thickening after vascular injury in dogs. These reports suggest that VEGF is indeed capable of inducing neointimal angiogenesis and intimal hyperplasia.
|
Acknowledgments |
|---|
This work was supported in part by research grants from the Japanese Ministry of Education, Science, and Culture; the Smoking Research Foundation; and the Japanese Heart Foundation.
Received January 22, 1998; revision received July 7, 1998; accepted July 11, 1998.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983–985.
2. Ferrara N, Bunting S. Vascular endothelial growth factor, a specific regulator of angiogenesis. Curr Opin Nephrol Hypertens. 1996;5:35–44.[Medline] [Order article via Infotrieve]
3. Millauer B, Wizigmann VS, Schnurch H, Martinez R, Moller NP, Risau W, Ullrich A. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell. 1993;72:835–846.[Medline] [Order article via Infotrieve]
4.
De Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N,
Williams LT. The fms-like tyrosine kinase, a receptor for vascular
endothelial growth factor. Science. 1992;255:989–991.
5. Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature. 1995;376:66–70.[Medline] [Order article via Infotrieve]
6. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 1995;376:62–66.[Medline] [Order article via Infotrieve]
7.
Shen H, Clauss M, Ryan J, Schmidt AM, Tijburg P,
Borden L, Connolly D, Stern D, Kao J. Characterization of vascular
permeability factor/vascular endothelial growth factor
receptors on mononuclear phagocytes. Blood. 1993;81:2767–2773.
8.
Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A,
Marme D. Migration of human monocytes in response to vascular
endothelial growth factor (VEGF) is mediated via the
VEGF receptor flt-1. Blood. 1996;87:3336–3343.
9.
Clauss M, Gerlach M, Gerlach H, Brett J, Wang F,
Familletti PC, Pan YC, Olander JV, Connolly DT, Stern D. Vascular
permeability factor: a tumor-derived polypeptide that induces
endothelial cell and monocyte procoagulant activity,
and promotes monocyte migration. J Exp Med. 1990;172:1535–1545.
10.
Doi K, Itoh H, Komatsu Y, Igaki T, Chun TH, Takaya K,
Yamashita J, Inoue M, Yoshimasa T, Nakao K. Vascular
endothelial growth factor suppresses C-type
natriuretic peptide secretion. Hypertension. 1996;27:811–815.
11.
Williams B, Baker AQ, Gallacher B, Lodwick D.
Angiotensin II increases vascular permeability factor gene
expression by human vascular smooth muscle cells.
Hypertension. 1995;25:913–917.
12. Berse B, Brown LF, van de Water L, Dvorak HF, Senger DR. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell. 1992;3:211–220.[Abstract]
13.
Namiki A, Brogi E, Kearney M, Kim EA, Wu T, Couffinhal
T, Varticovski L, Isner JM. Hypoxia induces vascular
endothelial growth factor in cultured human
endothelial cells. J Biol Chem. 1995;270:31189–31195.
14. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801–809.[Medline] [Order article via Infotrieve]
15. O'Brien ER, Garvin MR, Dev R, Stewart DK, Hinohara T, Simpson JB, Schwartz SM. Angiogenesis in human coronary atherosclerotic plaques. Am J Pathol. 1994;145:883–894.[Abstract]
16. Van der Wal AC, Becker AE, Van der Loos CM, Tigges AJ, Das PK. Fibrous and lipid-rich atherosclerotic plaques are part of interchangeable morphologies related to inflammation: a concept. Coron Artery Dis. 1994;5:463–469.[Medline] [Order article via Infotrieve]
17.
Naruko T, Ueda M, van der Wal AC, van der Loos CM, Itoh
H, Nakao K, Becker AE. C-type natriuretic peptide in human
coronary atherosclerotic lesions. Circulation. 1996;94:3103–3108.
18. Vinores SA, Kuchle M, Mahlow J, Chiu C, Green WR, Campochiaro PA. Blood-ocular barrier breakdown in eyes with ocular melanoma: a potential role for vascular endothelial growth factor/vascular permeability factor. Am J Pathol. 1995;147:1289–1297.[Abstract]
19. van der Wal AC, Das PK, van de Berg DB, van der Loos CM, Becker AE. Atherosclerotic lesions in humans: in situ immunophenotypic analysis suggesting an immune mediated response. Lab Invest. 1989;61:166–170.[Medline] [Order article via Infotrieve]
20.
Ueda M, Becker AE, Tsukada T, Numano F, Fujimoto T.
Fibrocellular tissue response after percutaneous
transluminal coronary angioplasty: an immunocytochemical
analysis of the cellular composition. Circulation. 1991;83:1327–1332.
21. Ueda M, Becker AE, Naruko T, Kojima A. Smooth muscle cell de-differentiation is a fundamental change preceding wound healing after percutaneous transluminal coronary angioplasty in humans. Coron Artery Dis. 1995;6:71–81.[Medline] [Order article via Infotrieve]
22.
Tanizawa S, Ueda M, van der Loos CM, van der Wal AC,
Becker AE. Expression of platelet-derived growth factor B chain and
platelet-derived growth factor ß receptor in human
coronary arteries after percutaneous
transluminal coronary angioplasty: an immunohistochemical
study. Heart. 1996;75:549–556.
23. Ueda M, Becker AE, Kasayuki N, Kojima A, Morita Y, Tanaka S. In situ detection of platelet-derived growth factor-A and -B chain mRNA in human coronary arteries after percutaneous transluminal coronary angioplasty. Am J Pathol. 1996;149:831–843.[Abstract]
24. van der Loos CM, Becker AE, van den Oord JJ. Practical suggestions for successful immunoenzyme double-staining experiments. Histochem J. 1993;25:1–13.[Medline] [Order article via Infotrieve]
25. Pepper MS, Ferrara N, Orci L, Montesano R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun. 1991;181:902–906.[Medline] [Order article via Infotrieve]
26.
Brown LF, Yeo KT, Berse B, Yeo TK, Senger DR, Dvorak
HF, van de Water L. Expression of vascular permeability factor
(vascular endothelial growth factor) by epidermal
keratinocytes during wound healing. J Exp
Med. 1992;176:1375–1379.
27. Barger AC, Beeuwkes R III, Lainey LL, Silverman KJ. Hypothesis: vasa vasorum and neovascularization of human coronary arteries: a possible role in the pathophysiology of atherosclerosis. N Engl J Med. 1984;310:175–177.[Medline] [Order article via Infotrieve]
28. Takeshita S, Zheng LP, Brogi E, Kearney M, Pu LQ, Bunting S, Ferrara N, Symes JF, Isner JM. Therapeutic angiogenesis: a single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest. 1994;93:662–670.
29. Isner JM, Walsh K, Symes J, Pieczek A, Takeshita S, Lowry J, Rosenfield K, Weir L, Brogi E, Jurayj D. Arterial gene transfer for therapeutic angiogenesis in patients with peripheral artery disease. Hum Gene Ther. 1996;7:959–988.[Medline] [Order article via Infotrieve]
30. Yonemitsu Y, Kaneda Y, Morishita R, Kazunori N, Nakashima Y, Sueishi K. Characterization of in vivo gene transfer into the arterial wall mediated by the Sendai virus (hemagglutinating virus of Japan) liposomes: an effective tool for the in vivo study of arterial diseases. Lab Invest. 1996;75:313–323.[Medline] [Order article via Infotrieve]
31.
Lazarous DF, Shou M, Scheinowitz M, Hodge E, Thirumurti
V, Kitsiou AN, Stiber JA, Lobo AD, Hunsberger S, Guetta E, Epstein SE,
Unger EF. Comparative effects of basic fibroblast growth factor and
vascular endothelial growth factor on coronary
collateral development and the arterial response to injury.
Circulation. 1996;94:1074–1082.This study evaluated
the presence of vascular endothelial growth factor
(VEGF), a novel angiogenic factor, and its receptors (flt-1 and Flk-1)
in human coronary arteries by immunohistochemical staining and
RT-PCR. Normal coronary arteries were negative for VEGF. In
contrast, hypercellular atherosclerotic lesions and advanced
atheromatous plaques showed VEGF positivity of
activated endothelial cells,
macrophages, and partially differentiated smooth muscle cells;
in addition, microvessels formed within advanced or totally occlusive
lesions expressed VEGF. VEGF mRNA was also detected in
atheromatous plaques but not in normal
arterial segments. Flt-1 and Flk-1 positivity was detected
in occasional macrophages in atherosclerotic lesions and
activated endothelial cells of the microvessels
in totally occlusive lesions. These results suggest a possible role of
VEGF in the progression of human coronary
atherosclerosis as well as
recanalization of occluded vessels.
This article has been cited by other articles:
 |
|
 |
|
  D. M. Birk, J. Barbato, L. Mureebe, and R. A. Chaer Basic Science Review: Current Insights on the Biology and Clinical Aspects of VEGF Regulation Vascular and Endovascular Surgery, December 1, 2009; 42(6): 517 - 530. [Abstract] [PDF]
|
|
|
|
 |
|
 B-C Lee, H-C Hsu, W-Y I Tseng, M-Y M Su, S-Y Chen, Y-W Wu, K-L Chien, and M-F Chen Effect of cardiac rehabilitation on angiogenic cytokines in postinfarction patients Heart, June 15, 2009; 95(12): 1012 - 1018. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Lieb, R. Safa, E. J. Benjamin, V. Xanthakis, X. Yin, L. M. Sullivan, M. G. Larson, H. M. Smith, J. A. Vita, G. F. Mitchell, et al. Vascular endothelial growth factor, its soluble receptor, and hepatocyte growth factor: clinical and genetic correlates and association with vascular function Eur. Heart J., May 1, 2009; 30(9): 1121 - 1127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Makino, J. Suarez, H. Wang, D. D. Belke, B. T. Scott, and W. H. Dillmann Thyroid Hormone Receptor-{beta} Is Associated with Coronary Angiogenesis during Pathological Cardiac Hypertrophy Endocrinology, April 1, 2009; 150(4): 2008 - 2015. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Hao, L. Wang, and H. Tang Vascular endothelial growth factor induces protein kinase D-dependent production of proinflammatory cytokines in endothelial cells Am J Physiol Cell Physiol, April 1, 2009; 296(4): C821 - C827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Nakashima, T. N. Wight, and K. Sueishi Early atherosclerosis in humans: role of diffuse intimal thickening and extracellular matrix proteoglycans Cardiovasc Res, July 1, 2008; 79(1): 14 - 23. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Kalka and I. Baumgartner Gene and stem cell therapy in peripheral arterial occlusive disease Vascular Medicine, May 1, 2008; 13(2): 157 - 172. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Misra, A. A. Fu, A. Puggioni, K. M. Karimi, J. N. Mandrekar, J. F. Glockner, L. A. Juncos, B. Anwer, A. M. McGuire, and D. Mukhopadhyay Increased shear stress with upregulation of VEGF-A and its receptors and MMP-2, MMP-9, and TIMP-1 in venous stenosis of hemodialysis grafts Am J Physiol Heart Circ Physiol, May 1, 2008; 294(5): H2219 - H2230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Cuaz-Perolin, L. Billiet, E. Bauge, C. Copin, D. Scott-Algara, F. Genze, B. Buchele, T. Syrovets, T. Simmet, and M. Rouis Antiinflammatory and Antiatherogenic Effects of the NF-{kappa}B Inhibitor Acetyl-11-Keto-{beta}-Boswellic Acid in LPS-Challenged ApoE-/- Mice Arterioscler. Thromb. Vasc. Biol., February 1, 2008; 28(2): 272 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Horvath and Y. Zhou Transmyocardial Laser Revascularization and Extravascular Angiogenetic Techniques to Increase Myocardial Blood Flow Card. Surg. Adult, January 1, 2008; 3(2008): 733 - 752. [Full Text]
|
|
|
|
 |
|
 M. Nachtigal, A. Ghaffar, and E. P. Mayer Galectin-3 Gene Inactivation Reduces Atherosclerotic Lesions and Adventitial Inflammation in ApoE-Deficient Mice Am. J. Pathol., January 1, 2008; 172(1): 247 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Barbieri and B. B. Weksler Tobacco smoke cooperates with interleukin-1{beta} to alter {beta}-catenin trafficking in vascular endothelium resulting in increased permeability and induction of cyclooxygenase-2 expression in vitro and in vivo FASEB J, June 1, 2007; 21(8): 1831 - 1843. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Doyle and N. Caplice Plaque Neovascularization and Antiangiogenic Therapy for Atherosclerosis J. Am. Coll. Cardiol., May 29, 2007; 49(21): 2073 - 2080. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-Y. Chyu and P. K. Shah Choking off Plaque Neovascularity: A Promising Atheroprotective Strategy or A Double-Edged Sword? Arterioscler. Thromb. Vasc. Biol., May 1, 2007; 27(5): 993 - 995. [Full Text] [PDF]
|
|
|
|
|
|
R. J. Petrovan, C. D. Kaplan, R. A. Reisfeld, and L. K. Curtiss DNA Vaccination Against VEGF Receptor 2 Reduces Atherosclerosis in LDL Receptor-Deficient Mice Arterioscler. Thromb. Vasc. Biol., May 1, 2007; 27(5): 1095 - 1100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Jaumdally, C. Varma, R. J. Macfadyen, and G. Y.H. Lip Coronary sinus blood sampling: an insight into local cardiac pathophysiology and treatment? Eur. Heart J., April 2, 2007; 28(8): 929 - 940. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yla-Herttuala, T. T. Rissanen, I. Vajanto, and J. Hartikainen Vascular Endothelial Growth Factors: Biology and Current Status of Clinical Applications in Cardiovascular Medicine J. Am. Coll. Cardiol., March 13, 2007; 49(10): 1015 - 1026. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Herrmann, L. O. Lerman, D. Mukhopadhyay, C. Napoli, and A. Lerman Angiogenesis in Atherogenesis Arterioscler. Thromb. Vasc. Biol., September 1, 2006; 26(9): 1948 - 1957. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schmeisser, M. Christoph, A. Augstein, R. Marquetant, M. Kasper, R.C. Braun-Dullaeus, and R.H. Strasser Apoptosis of human macrophages by Flt-4 signaling: Implications for atherosclerotic plaque pathology Cardiovasc Res, September 1, 2006; 71(4): 774 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Saeed, A. J. Martin, R. J. Lee, O. Weber, D. Revel, D. Saloner, and C. B. Higgins MR Guidance of Targeted Injections into Border and Core of Scarred Myocardium in Pigs Radiology, August 1, 2006; 240(2): 419 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Wang, D. Mukhopadhyay, and X. Xu C terminus of RGS-GAIP-interacting protein conveys neuropilin-1-mediated signaling during angiogenesis FASEB J, July 1, 2006; 20(9): 1513 - 1515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Fujita, M. Yoshizumi, Y. Izawa, N. Ali, H. Ohnishi, Y. Kanematsu, K. Ishizawa, K. Tsuchiya, and T. Tamaki Transactivation of Fetal Liver Kinase-1/Kinase-Insert Domain-Containing Receptor by Lysophosphatidylcholine Induces Vascular Endothelial Cell Proliferation Endocrinology, March 1, 2006; 147(3): 1377 - 1385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Pinheiro, C. M. Castro, and V. L. Szejnfeld Low femoral bone mineral density and quantitative ultrasound are risk factors for new osteoporotic fracture and total and cardiovascular mortality: a 5-year population-based study of brazilian elderly women. J. Gerontol. A Biol. Sci. Med. Sci., February 1, 2006; 61(2): 196 - 203. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Dulak, S. P Schwarzacher, R. H Zwick, H. Alber, G. Millonig, C. Weiss, H. Hugel, M. Frick, A. Jozkowicz, O. Pachinger, et al. Effects of local gene transfer of VEGF on neointima formation after balloon injury in hypercholesterolemic rabbits Vascular Medicine, November 1, 2005; 10(4): 285 - 291. [Abstract] [PDF]
|
|
|
|
|
|
M. Garcia-Ramirez, J. Martinez-Gonzalez, J. O. Juan-Babot, C. Rodriguez, and L. Badimon Transcription Factor SOX18 Is Expressed in Human Coronary Atherosclerotic Lesions and Regulates DNA Synthesis and Vascular Cell Growth Arterioscler. Thromb. Vasc. Biol., November 1, 2005; 25(11): 2398 - 2403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Baba, Y. Yonemitsu, T. Nakano, M. Onimaru, M. Miyazaki, Y. Ikeda, S. Sumiyoshi, Y. Ueda, M. Hasegawa, I. Yoshino, et al. Cytoplasmic Expression and Extracellular Deposition of an Antiangiogenic Factor, Pigment Epithelium-Derived Factor, in Human Atherosclerotic Plaques Arterioscler. Thromb. Vasc. Biol., September 1, 2005; 25(9): 1938 - 1944. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Leppanen, S. Koota, I. Kholova, J. Koponen, C. Fieber, U. Eriksson, K. Alitalo, and S. Yla-Herttuala Gene Transfers of Vascular Endothelial Growth Factor-A, Vascular Endothelial Growth Factor-B, Vascular Endothelial Growth Factor-C, and Vascular Endothelial Growth Factor-D Have No Effects on Atherosclerosis in Hypercholesterolemic Low-Density Lipoprotein-Receptor/Apolipoprotein B48-Deficient Mice Circulation, August 30, 2005; 112(9): 1347 - 1352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Yau, G. Li, Y. Zhang, R. D. Weisel, D. A.G. Mickle, and R.-K. Li Vascular Endothelial Growth Factor Receptor Upregulation in Response to Cell-Based Angiogenic Gene Therapy Ann. Thorac. Surg., June 1, 2005; 79(6): 2056 - 2063. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Costa and D. I. Simon Molecular Basis of Restenosis and Drug-Eluting Stents Circulation, May 3, 2005; 111(17): 2257 - 2273. [Full Text] [PDF]
|
|
|
|
|
|
G. A. Krombach, J. G. Pfeffer, S. Kinzel, M. Katoh, R. W. Gunther, and A. Buecker MR-guided Percutaneous Intramyocardial Injection with an MR-compatible Catheter: Feasibility and Changes in T1 Values after Injection of Extracellular Contrast Medium in Pigs Radiology, May 1, 2005; 235(2): 487 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Coats and R. Wadsworth Marriage of resistance and conduit arteries breeds critical limb ischemia Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1044 - H1050. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Reinhardt, P. Schaarschmidt, A. Bossert, A. Luske, G. Finkenzeller, T. Mertens, and D. Michel Upregulation of functionally active vascular endothelial growth factor by human cytomegalovirus J. Gen. Virol., January 1, 2005; 86(1): 23 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. O'Riain, D. J. Buggy, M. J. Kerin, R. W. G. Watson, and D. C. Moriarty Inhibition of the Stress Response to Breast Cancer Surgery by Regional Anesthesia and Analgesia Does Not Affect Vascular Endothelial Growth Factor and Prostaglandin E2 Anesth. Analg., January 1, 2005; 100(1): 244 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hoeben, B. Landuyt, M. S. Highley, H. Wildiers, A. T. Van Oosterom, and E. A. De Bruijn Vascular Endothelial Growth Factor and Angiogenesis Pharmacol. Rev., December 1, 2004; 56(4): 549 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Zhao, K. Egashira, K.-i. Hiasa, M. Ishibashi, S. Inoue, K. Ohtani, C. Tan, M. Shibuya, A. Takeshita, and K. Sunagawa Essential Role of Vascular Endothelial Growth Factor and Flt-1 Signals in Neointimal Formation After Periadventitial Injury Arterioscler. Thromb. Vasc. Biol., December 1, 2004; 24(12): 2284 - 2289. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Sharif, K. Daly, J. Crowley, and T. O'Brien Current status of catheter- and stent-based gene therapy Cardiovasc Res, November 1, 2004; 64(2): 208 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ohtani, K. Egashira, K.-i. Hiasa, Q. Zhao, S. Kitamoto, M. Ishibashi, M. Usui, S. Inoue, Y. Yonemitsu, K. Sueishi, et al. Blockade of Vascular Endothelial Growth Factor Suppresses Experimental Restenosis After Intraluminal Injury by Inhibiting Recruitment of Monocyte Lineage Cells Circulation, October 19, 2004; 110(16): 2444 - 2452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Murdoch, A. Giannoudis, and C. E. Lewis Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues Blood, October 15, 2004; 104(8): 2224 - 2234. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Epstein, E. Stabile, T. Kinnaird, C. W. Lee, L. Clavijo, and M. S. Burnett Janus Phenomenon: The Interrelated Tradeoffs Inherent in Therapies Designed to Enhance Collateral Formation and Those Designed to Inhibit Atherogenesis Circulation, June 15, 2004; 109(23): 2826 - 2831. [Full Text] [PDF]
|
|
|
|
|
|
M. Saeed, R. Lee, A. Martin, O. Weber, G. A. Krombach, S. Schalla, M. Lee, D. Saloner, and C. B. Higgins Transendocardial Delivery of Extracellular Myocardial Markers by Using Combination X-ray/MR Fluoroscopic Guidance: Feasibility Study in Dogs Radiology, June 1, 2004; 231(3): 689 - 696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.H. Tayebjee, G.Y.H. Lip, and R.J. MacFadyen Collateralization and the response to obstruction of epicardial coronary arteries QJM, May 1, 2004; 97(5): 259 - 272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F Belgore, A Blann, D Neil, A S Ahmed, and G Y H Lip Localisation of members of the vascular endothelial growth factor (VEGF) family and their receptors in human atherosclerotic arteries J. Clin. Pathol., March 1, 2004; 57(3): 266 - 272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Rutanen, P. Leppanen, T. T Tuomisto, T. T Rissanen, M. O Hiltunen, I. Vajanto, M. Niemi, T. Hakkinen, K. Karkola, S. A Stacker, et al. Vascular endothelial growth factor-D expression in human atherosclerotic lesions Cardiovasc Res, October 1, 2003; 59(4): 971 - 979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Santos, V. I. Peinado, J. Ramirez, J. Morales-Blanhir, R. Bastos, J. Roca, R. Rodriguez-Roisin, and J. A. Barbera Enhanced Expression of Vascular Endothelial Growth Factor in Pulmonary Arteries of Smokers and Patients with Moderate Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., May 1, 2003; 167(9): 1250 - 1256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Lenihan, A. Osman, V. Sriram, J. Aitsebaomo, and C. Patterson Evidence for association of coronary sinus levels of hepatocyte growth factor and collateralization in human coronary disease Am J Physiol Heart Circ Physiol, May 1, 2003; 284(5): H1507 - H1512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.C Felmeden, A.D Blann, and G.Y.H Lip Angiogenesis: basic pathophysiology and implications for disease Eur. Heart J., April 1, 2003; 24(7): 586 - 603. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Yamahara, H. Itoh, T.-H. Chun, Y. Ogawa, J. Yamashita, N. Sawada, Y. Fukunaga, M. Sone, T. Yurugi-Kobayashi, K. Miyashita, et al. Significance and therapeutic potential of the natriuretic peptides/cGMP/cGMP-dependent protein kinase pathway in vascular regeneration PNAS, March 18, 2003; 100(6): 3404 - 3409. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-S. Silvestre, N. Kamsu-Kom, M. Clergue, M. Duriez, and B. I. Levy Very-Low-Dose Combination of the Angiotensin-Converting Enzyme Inhibitor Perindopril and the Diuretic Indapamide Induces an Early and Sustained Increase in Neovascularization in Rat Ischemic Legs J. Pharmacol. Exp. Ther., December 1, 2002; 303(3): 1038 - 1043. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kobayashi and K. Kamata Short-term insulin treatment and aortic expressions of IGF-1 receptor and VEGF mRNA in diabetic rats Am J Physiol Heart Circ Physiol, November 1, 2002; 283(5): H1761 - H1768. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N.A.Y. Chung, C. Lydakis, F. Belgore, A.D. Blann, and G.Y.H. Lip Angiogenesis in myocardial infarction. An acute or chronic process? Eur. Heart J., October 2, 2002; 23(20): 1604 - 1608. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. A.Y. Chung, F. Belgore, F. L. Li-Saw-Hee, D. S.G. Conway, A. D. Blann, and G. Y.H. Lip Is the Hypercoagulable State in Atrial Fibrillation Mediated by Vascular Endothelial Growth Factor? Stroke, September 1, 2002; 33(9): 2187 - 2191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Franz Alber, J. Dulak, M. Frick, W. Dichtl, S. Paul Schwarzacher, O. Pachinger, and F. Weidinger Atorvastatin decreases vascular endothelial growth factor in patients with coronary artery disease J. Am. Coll. Cardiol., June 19, 2002; 39(12): 1951 - 1955. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Lavie, H. Kraiczi, A. Hefetz, H. Ghandour, A. Perelman, J. Hedner, and P. Lavie Plasma Vascular Endothelial Growth Factor in Sleep Apnea Syndrome: Effects of Nasal Continuous Positive Air Pressure Treatment Am. J. Respir. Crit. Care Med., June 15, 2002; 165(12): 1624 - 1628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.M. Cotton, A. Mathur, Y. Hong, A.S. Brown, J.F. Martin, and J.D. Erusalimsky Acute rise of circulating vascular endothelial growth factor-A in patients with coronary artery disease following cardiothoracic surgery Eur. Heart J., June 2, 2002; 23(12): 953 - 959. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. S. Conklin, W. Zhao, D.-S. Zhong, and C. Chen Nicotine and Cotinine Up-Regulate Vascular Endothelial Growth Factor Expression in Endothelial Cells Am. J. Pathol., February 1, 2002; 160(2): 413 - 418. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.S. MOULTON Plaque Angiogenesis: Its Functions and Regulation Cold Spring Harb Symp Quant Biol, January 1, 2002; 67(0): 471 - 482. [Abstract] [PDF]
|
|
|
|
 |
|
 R. I. Clyman, S. R. Seidner, H. Kajino, C. Roman, C. J. Koch, N. Ferrara, N. Waleh, F. Mauray, Y. Q. Chen, E. A. Perkett, et al. VEGF regulates remodeling during permanent anatomic closure of the ductus arteriosus Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2002; 282(1): R199 - R206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Dulak, A. Jozkowicz, M. Frick, H. F. Alber, W. Dichtl, S. P. Schwarzacher, O. Pachinger, and F. Weidinger Vascular endothelial growth factor: angiogenesis, atherogenesis or both? J. Am. Coll. Cardiol., December 1, 2001; 38(7): 2137 - 2138. [Full Text] [PDF]
|
|
|
|
|
|
J. Herrmann, L. O Lerman, M. Rodriguez-Porcel, D. R Holmes Jr., D. M Richardson, E. L Ritman, and A. Lerman Coronary vasa vasorum neovascularization precedes epicardial endothelial dysfunction in experimental hypercholesterolemia Cardiovasc Res, September 1, 2001; 51(4): 762 - 766. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Isner, P. R. Vale, J. F. Symes, and D. W. Losordo Assessment of Risks Associated With Cardiovascular Gene Therapy in Human Subjects Circ. Res., August 31, 2001; 89(5): 389 - 400. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Epstein, R. Kornowski, S. Fuchs, and H. F. Dvorak Angiogenesis Therapy : Amidst the Hype, the Neglected Potential for Serious Side Effects Circulation, July 3, 2001; 104(1): 115 - 119. [Full Text] [PDF]
|
|
|
|
|
|
M. Kuzuya, M. A. Ramos, S. Kanda, T. Koike, T. Asai, K. Maeda, K. Shitara, M. Shibuya, and A. Iguchi VEGF Protects Against Oxidized LDL Toxicity to Endothelial Cells by an Intracellular Glutathione-Dependent Mechanism Through the KDR Receptor Arterioscler. Thromb. Vasc. Biol., May 1, 2001; 21(5): 765 - 770. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Inoue, H. Itoh, T. Tanaka, T.-H. Chun, K. Doi, Y. Fukunaga, N. Sawada, J. Yamshita, K. Masatsugu, T. Saito, et al. Oxidized LDL Regulates Vascular Endothelial Growth Factor Expression in Human Macrophages and Endothelial Cells Through Activation of Peroxisome Proliferator-Activated Receptor-{{gamma}} Arterioscler. Thromb. Vasc. Biol., April 1, 2001; 21(4): 560 - 566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Epstein, S. Fuchs, Y. F. Zhou, R. Baffour, and R. Kornowski Therapeutic interventions for enhancing collateral development by administration of growth factors: basic principles, early results and potential hazards Cardiovasc Res, February 16, 2001; 49(3): 532 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Brizzi, L. Formato, P. Dentelli, A. Rosso, M. Pavan, G. Garbarino, M. Pegoraro, G. Camussi, and L. Pegoraro Interleukin-3 Stimulates Migration and Proliferation of Vascular Smooth Muscle Cells : A Potential Role in Atherogenesis Circulation, January 30, 2001; 103(4): 549 - 554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Bausero, M.-H. Ben-Mahdi, J.-P. Mazucatelli, C. Bloy, and M. Perrot-Applanat Vascular endothelial growth factor is modulated in vascular muscle cells by estradiol, tamoxifen, and hypoxia Am J Physiol Heart Circ Physiol, November 1, 2000; 279(5): H2033 - H2042. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Dahlfors and H. J. Arnqvist Vascular Endothelial Growth Factor and Transforming Growth Factor-{beta}1 Regulate the Expression of Insulin-Like Growth Factor-Binding Protein-3, -4, and -5 in Large Vessel Endothelial Cells Endocrinology, June 1, 2000; 141(6): 2062 - 2067. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. W. Griffioen and G. Molema Angiogenesis: Potentials for Pharmacologic Intervention in the Treatment of Cancer, Cardiovascular Diseases, and Chronic Inflammation Pharmacol. Rev., June 1, 2000; 52(2): 237 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Ollivier, J. Chabbat, J. M. Herbert, J. Hakim, and D. de Prost Vascular Endothelial Growth Factor Production by Fibroblasts in Response to Factor VIIa Binding to Tissue Factor Involves Thrombin and Factor Xa Arterioscler. Thromb. Vasc. Biol., May 1, 2000; 20(5): 1374 - 1381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Dong and P. J. Goldschmidt-Clermont Bone Sialoprotein and the Paradox of Angiogenesis Versus Atherosclerosis Circ. Res., April 28, 2000; 86(8): 827 - 828. [Full Text] [PDF]
|
|
|
|
 |
|
 B J Hunt The endothelium in atherogenesis Lupus, March 1, 2000; 9(3): 189 - 193. [Abstract] [PDF]
|
|
|
|
|
|
N. Akuzawa, M. Kurabayashi, Y. Ohyama, M. Arai, and R. Nagai Zinc Finger Transcription Factor Egr-1 Activates Flt-1 Gene Expression in THP-1 Cells on Induction for Macrophage Differentiation Arterioscler. Thromb. Vasc. Biol., February 1, 2000; 20(2): 377 - 384. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kornowski, S. Fuchs, M. B. Leon, and S. E. Epstein Delivery Strategies to Achieve Therapeutic Myocardial Angiogenesis Circulation, February 1, 2000; 101(4): 454 - 458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sinnaeve, O. Varenne, D. Collen, and S. Janssens Gene therapy in the cardiovascular system: an update Cardiovasc Res, December 1, 1999; 44(3): 498 - 506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Moussa and J. W. Moses Angiogenesis for Treatment of Ischemic Heart Disease: Should We Worry About Progression of Atherosclerosis? Circulation, November 30, 1999; 100 (22): e109 - e109. [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Chambers, S. T Riebel, and M. Kozak Interventional Cardiology: Advances in Percutaneous Techniques for the Treatment of Cardiac Disease Seminars in Cardiothoracic and Vascular Anesthesia, July 1, 1999; 3(2): 109 - 125. [Abstract] [PDF]
|
|
|
|
 |
|
 T. D Henry Science, medicine, and the future: Therapeutic angiogenesis BMJ, June 5, 1999; 318(7197): 1536 - 1539. [Full Text]
|
|
|
|
|
|
C. K. Sen, S. Khanna, M. Venojarvi, P. Trikha, E. C. Ellison, T. K. Hunt, and S. Roy Copper-induced vascular endothelial growth factor expression and wound healing Am J Physiol Heart Circ Physiol, May 1, 2002; 282(5): H1821 - H1827. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||